Alpha v integrin receptor antagonists
US7056909B2 · kind B2 · utility
17Cited by
1References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 20, 2001 |
| Grant date | Jun 6, 2006 |
| Priority date | — |
| Expiry date | Oct 15, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D213/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel chain-fluorinated alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.